Released May 6, 2021, after the close
10-Q filed May 6, 2021, 36 days after period end · 0001564590-21-025060
Q1 2021 · 10-Q
Revenue—
Net Income-$27.20M-$27.20M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.69-$0.69 N/M vs Q1 2020N/M vs Q4 2020
Operating Income-$27,258,000N/M
Operating Cash Flow-$33,344,000N/M
Free Cash Flowderived-$36,422,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | — | $4.08M | $3.89M | $3.57M |
| Net Income | -$27.20M | -$26.66M | -$27.05M | -$16.25M |
| EPS Diluted | -$0.69 | -$0.76 | -$1.05 | -$0.80 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR